Atlas Trials

Recurrent Multiple Myeloma

30 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Multiple Myeloma

RecordFirmDate
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT04883242)University of Washington2021-07-29
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial (NCT04764942)Mayo Clinic2021-05-06
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment (NCT03770260)National Cancer Institute (NCI)2020-02-10
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (NCT03798678)National Cancer Institute (NCI)2019-07-08
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (NCT03031730)National Cancer Institute (NCI)2018-06-14
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients (NCT03618602)Shanghai Theorion Pharmaceutical Co Ltd.2018-04-25
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT03389347)University of Washington2018-02-14
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060)National Cancer Institute (NCI)2015-08-17
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02101944)National Cancer Institute (NCI)2014-12-09

Track Recurrent Multiple Myeloma automatically

Every clearance here is in the API, with alerts when new ones post.